Home News Cannibus Coke? Coca-Cola is Considering Using CBD Oils in Products

Cannibus Coke? Coca-Cola is Considering Using CBD Oils in Products

Coke with CBD is not manufactured yet, this is actually a stevia product line, for healthier enjoyment

CIRCLEVILLE – CBD is the abbreviation for Cannabidiol, a cannabinoid that is extracted from the cannabis plant. The products sold by CBD Oil Solutions are all extracted from federally legal Industrial Hemp plants, part of the cannabis sativa family. These plants are grown legally under the United States Farm Bill of 2014 signed by President Barack Obama, the 44th President of the United States of America.

According to Bloomberg.com “Coke-Cola is exploring the possibility of using CBD oil as a infusion in its “wellness beverages” to ease inflammation, pain and cramping.”

Forbes predicts a 700% increase in the CBD market by 2020 and market intelligence firm Hemp Business Journal projects that the CBD market will grow to $2.1 billion by 2020 as well. This is a jump of over 900% in value compared to 2016’s CBD market of $202 million. The World Health Organization (WHO) recently released a preliminary report regarding CBD and stated “To date, there is no evidence of recreational use of CBD or any public health related problems associated with the use of pure CBD,” and that CBD is “not associated with abuse potential.” The World Health Organization team went on to state that CBD has “been demonstrated as an effective treatment.”

Hemp grown under the industrial hemp farming act contains less than 0.3% THC. THC is the shortened abbreviation for Tetrahydrocannabinol which is a psychotropic cannabinoid that is derived from the cannabis marijuana plant. Hemp CBD products contain no psychoactive effects as they contain anywhere from absolute zero to 0.3% or less THC.

A statement from FDA talks about the advances in CBD oils and the legalities of it thus far, “Over the past decade, we’ve seen a growing interest in the development of therapies derived from marijuana and its components. Proponents of “medical marijuana” advertised its uses for a wide number of medical conditions, such as cancer, multiple sclerosis, post-traumatic stress disorder and anxiety – just to name a few of the touted conditions. The FDA has been supportive of research in this area for many years. But marijuana is a Schedule I compound with known risks. Research to demonstrate that marijuana or its components could be safe and effective in the treatment of medical disorders should be held to the same standard as other drug compounds. And certainly it should not be held to a lower standard, as some proponents would suggest. The FDA has an active program to assist drug developers who want to investigate marijuana or its components through properly controlled clinical trials, to demonstrate the potential for safe and effective uses.

Today, the FDA approved a purified form of the drug cannabidiol (CBD). This is one of more than 80 active chemicals in marijuana. The new product was approved to treat seizures associated with two rare, severe forms of epilepsy in patients two years of age and older.

This product approval demonstrates that advancing sound scientific research to investigate ingredients derived from marijuana can lead to important therapies. This new treatment provides new options for patients.

This is an important medical advance. But it’s also important to note that this is not an approval of marijuana or all of its components. This is the approval of one specific CBD medication for a specific use. And it was based on well-controlled clinical trials evaluating the use of this compound in the treatment of a specific condition. Moreover, this is a purified form of CBD. It’s being delivered to patients in a reliable dosage form and through a reproducible route of delivery to ensure that patients derive the anticipated benefits. This is how sound medical science is advanced.”